Karen Knudsen

Summary

Publications

  1. pmc RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response
    Adam Ertel
    Kimmel Cancer Center, Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
    Cell Cycle 9:4153-63. 2010
  2. pmc AR, the cell cycle, and prostate cancer
    Steven P Balk
    Cancer Biology Program Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Nucl Recept Signal 6:e001. 2008
  3. pmc mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
    Matthew J Schiewer
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Endocr Relat Cancer 19:1-12. 2012
  4. pmc A tale of three PKCs: Epsilon emerges as a driver of pre-neoplastic phenotypes
    Karen E Knudsen
    Thomas Jefferson University and Kimmel Cancer Center Philadelphia, PA
    Cell Cycle 10:380-79. 2011
  5. pmc Cyclin D1 goes metabolic: Dual functions of cyclin D1 in regulating lipogenesis
    Karen E Knudsen
    Departments of Cancer Biology, Urology and Radiation Oncology Thomas Jefferson University and Kimmel Cancer Center Philadelphia, PA USA
    Cell Cycle 11:3534. 2012
  6. pmc Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer
    M J Schiewer
    Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Oncogene 28:1016-27. 2009
  7. pmc Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer
    Karen E Knudsen
    Departments of Cancer Biology, Urology, and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Cancer Res 15:4792-8. 2009
  8. pmc Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
    Karen E Knudsen
    Kimmel Cancer Center, Department of Cancer Biology and Department of Urology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Trends Endocrinol Metab 21:315-24. 2010
  9. pmc Tailoring to RB: tumour suppressor status and therapeutic response
    Erik S Knudsen
    Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Nat Rev Cancer 8:714-24. 2008
  10. doi request reprint 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways
    Supriya Shah
    Kimmel Cancer Center and Department of Cancer, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Mol Cancer Res 6:1507-20. 2008

Collaborators

Detail Information

Publications12

  1. pmc RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response
    Adam Ertel
    Kimmel Cancer Center, Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
    Cell Cycle 9:4153-63. 2010
    ....
  2. pmc AR, the cell cycle, and prostate cancer
    Steven P Balk
    Cancer Biology Program Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Nucl Recept Signal 6:e001. 2008
    ..As will be discussed, discrete aberrations in this process can alter the proliferative response to androgen, and potentially subvert hormonal control of tumor progression...
  3. pmc mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
    Matthew J Schiewer
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Endocr Relat Cancer 19:1-12. 2012
    ..Taken together, these data demonstrate that inhibition of mTOR confers a radiosensitization phenotype that is dependent on relative cell cycle kinetics and provide a foundation for clinical assessment...
  4. pmc A tale of three PKCs: Epsilon emerges as a driver of pre-neoplastic phenotypes
    Karen E Knudsen
    Thomas Jefferson University and Kimmel Cancer Center Philadelphia, PA
    Cell Cycle 10:380-79. 2011
    ..Comment on: Benavides F, et al. Cell Cycle 2011; 10:286-77:  ..
  5. pmc Cyclin D1 goes metabolic: Dual functions of cyclin D1 in regulating lipogenesis
    Karen E Knudsen
    Departments of Cancer Biology, Urology and Radiation Oncology Thomas Jefferson University and Kimmel Cancer Center Philadelphia, PA USA
    Cell Cycle 11:3534. 2012
    ..Comment on: Hanse EA, et al. Cell Cycle 2012; 11:2681-90...
  6. pmc Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer
    M J Schiewer
    Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Oncogene 28:1016-27. 2009
    ....
  7. pmc Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer
    Karen E Knudsen
    Departments of Cancer Biology, Urology, and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Cancer Res 15:4792-8. 2009
    ....
  8. pmc Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
    Karen E Knudsen
    Kimmel Cancer Center, Department of Cancer Biology and Department of Urology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Trends Endocrinol Metab 21:315-24. 2010
    ..In this report, the mechanisms underlying the lethal pairing of AR deregulation and aberrant androgen synthesis in prostate cancer progression will be discussed...
  9. pmc Tailoring to RB: tumour suppressor status and therapeutic response
    Erik S Knudsen
    Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Nat Rev Cancer 8:714-24. 2008
    ..Particularly, loss of RB function is associated with differential response to wide-ranging therapeutic agents. Thus, the status of this tumour suppressor may be particularly informative in directing treatment regimens...
  10. doi request reprint 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways
    Supriya Shah
    Kimmel Cancer Center and Department of Cancer, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Mol Cancer Res 6:1507-20. 2008
    ....
  11. pmc Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity
    Kevin A Link
    Departments of Cancer Biology and Urology, and Kimmel Cancer Center, Thomas Jefferson University College of Medicine, Philadelphia, Pennsylvania, USA
    Cancer Res 68:4551-8. 2008
    ....
  12. pmc Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer
    Clay E S Comstock
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Clin Cancer Res 15:5338-49. 2009
    ..Here, the frequency, tumor relevance, and mechanisms controlling cyclin D1b were challenged...

Research Grants22

  1. Role of BAF57 in AR control and prostate cancer growth
    Karen Knudsen; Fiscal Year: 2006
    ..Together, these studies will reveal the efficacy of BAF57 as a therapeutic target in both early and late stage prostate cancer. ..
  2. Targeting BRM as novel model of prostate hyperplasia
    Karen Knudsen; Fiscal Year: 2007
    ..The studies described will establish the utility of this model for analysis of prostate cancer, and reveal the biological consequence of BRM loss in the prostate. ..
  3. Cyclin D1: repercussions of AR control and alternative splicing in prostate cance
    Karen E Knudsen; Fiscal Year: 2010
    ..Here, we will determine molecular mechanisms through which cyclin D1 controls AR and determine the importance of this protein in prostate cancer, with the long term goal of devising new therapies to treat this deadly disease. ..
  4. Endocrine disruptors: AR regulation and prostate cancer
    Karen Knudsen; Fiscal Year: 2007
    ..Given the persistence of each studied EDC in the American population, these studies may have significant impact on understanding the factors that impinge upon prostate cancer growth. ..
  5. Endocrine disruptors: AR regulation and prostate cancer
    Karen E Knudsen; Fiscal Year: 2010
    ..Given the persistence of each studied EDC in the American population, these studies may have significant impact on understanding the factors that impinge upon prostate cancer growth. ..
  6. Bis-phenol A: Signaling and Mitogenesis in the Prostate
    Karen Knudsen; Fiscal Year: 2006
    ..abstract_text> ..
  7. Role of BAF57 in AR control and prostate cancer growth
    Karen E Knudsen; Fiscal Year: 2010
    ..Together, these studies will reveal the efficacy of BAF57 as a therapeutic target in both early and late stage prostate cancer. ..
  8. Cyclin D1: repercussions of AR control and alternative splicing in prostate cance
    Karen Knudsen; Fiscal Year: 2009
    ..Here, we will determine molecular mechanisms through which cyclin D1 controls AR and determine the importance of this protein in prostate cancer, with the long term goal of devising new therapies to treat this deadly disease. ..
  9. Role of BAF57 in AR control and prostate cancer growth
    Karen Knudsen; Fiscal Year: 2009
    ..Together, these studies will reveal the efficacy of BAF57 as a therapeutic target in both early and late stage prostate cancer. ..
  10. Cyclin D1: Mechanism and Consequence of Androgen Receptor Inhibition
    Karen Knudsen; Fiscal Year: 2007
    ..Given the importance of AR activity in the prostate tumor formation and progression, it is our belief that a better understanding of AR regulation is critical for the design of novel, effective therapeutics. ..